Surgical Management of Melanoma: Concept of Field Cancerization and Molecular Evaluation of Tissue Margins

  • Amanda PhelpsEmail author
  • Michael J. Murphy
Part of the Current Clinical Pathology book series (CCPATH)


The concept of field cancerization, first proposed by Slaughter in 1953, describes a process whereby cells in a particular tissue or organ are sequentially transformed by multiple cumulative genetic and epigenetic alterations, such that a clonal expansion of pre-neoplastic genetically-altered, but morphologically normal-appearing cells is present, prior to the development of overt malignancy. Additional genomic aberrations are required for cancer development, but these precursor cells may persist with the malignant cells of a tumor.


  1. 1.
    Dakubo GD, Jakupciak JP, Birch-Machin MA, et al. Clinical implications and utility of field cancerization. Cancer Cell Int. 2007;7:2.PubMedCrossRefGoogle Scholar
  2. 2.
    Murphy M. Molecular determination of tissue margins, clonal origin and histogenesis of skin cancers. In: Murphy MJ, editor. Molecular diagnostics in dermatology and dermatopathology. New York: Springer; 2011.CrossRefGoogle Scholar
  3. 3.
    Carlson JA, Murphy M, Slominski A, Wilson VL. Evidence of skin field cancerization. In: Dabuko GD, editor. Field cancerization: basic science and clinical applications. New York: Nova; 2011.Google Scholar
  4. 4.
    Bastian BC, Kashani-Sabet M, Hamm H, et al. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res. 2000;60:1968–73.PubMedGoogle Scholar
  5. 5.
    North JP, Kageshita T, Pinkel D, et al. Distribution and significance of occult intraepidermal tumor cells surrounding primary melanoma. J Invest Dermatol. 2008;128:2024–30.PubMedCrossRefGoogle Scholar
  6. 6.
    Hinshaw M. Use of genetic tools to control tumor margins in melanoma. Arch Dermatol. 2009;145: 475–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Takata M, Murata H, Saida T. Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma. Pigment Cell Melanoma Res. 2010;23:64–71.PubMedCrossRefGoogle Scholar
  8. 8.
    Takata M, Saida T. Early cancers of the skin: clinical, histopathological, and molecular characteristics. Int J Clin Oncol. 2005;10:391–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Whalen J, Leone D. Mohs micrographic surgery for the treatment of malignant melanoma. Clin Dermatol. 2009;27:597–602.PubMedCrossRefGoogle Scholar
  10. 10.
    Griego RD, Zitelli JA. Mohs micrographic surgery using HMB-45 for a recurrent acral melanoma. Dermatol Surg. 1998;24:1003–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Pashaei S, Li L, Zhang H, Spencer HJ, et al. Concordant loss of heterozygosity of DNA repair gene, hOGG1, in melanoma in situ and atypical melanocytic hyperplasia. J Cutan Pathol. 2008;35:525–31.PubMedCrossRefGoogle Scholar
  12. 12.
    Udart M, Utikal J, Krähn GM, Peter RU. Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. Neoplasia. 2001;3:245–54.PubMedCrossRefGoogle Scholar
  13. 13.
    Hubbard K, Steinberg ML, Hill H, et al. Mitochondrial DNA deletions in skin from melanoma patients. Ethn Dis. 2008;18(2 Suppl 2):S2-38–43.Google Scholar
  14. 14.
    Steinberg ML, Hubbard K, Utti C, et al. Patterns of persistent DNA damage associated with sun exposure and the glutathione S-transferase M1 genotype in melanoma patients. Photochem Photobiol. 2009;85:379–86.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Central Connecticut State UniversityNew BritainUSA
  2. 2.Department of DermatologyUniversity of Connecticut Health CenterFarmingtonUSA

Personalised recommendations